"Personalized Excision" of Malignant Melanoma-Need for a Paradigm Shift in the Beginning Era of Personalized Medicine

被引:9
|
作者
Weyers, Wolfgang [1 ]
机构
[1] Ctr Dermatopathol, Engelbergerstr 19, D-79106 Freiburg, Germany
关键词
melanoma; excision; margins; MOHS MICROGRAPHIC SURGERY; WIDE LOCAL EXCISION; CUTANEOUS MELANOMA; IN-SITU; HISTOPATHOLOGIC CRITERIA; PROGNOSTIC-FACTORS; RECURRENCE RATE; DONOR SITE; SKIN; METASTASES;
D O I
10.1097/DAD.0000000000001450
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The premises on which guidelines for the excision of primary cutaneous melanoma are based are illogical and fail to take into account peculiarities of the individual lesion. The horizontal margins of excision continue to be adjusted to the vertical thickness of the neoplasm, and recommended clinical margins do not reflect the histopathologic borders of melanoma. Micrographically controlled surgery has become accepted for acral melanomas and melanomas of the face and neck but not for melanomas on the trunk, arms, and legs, although the latter tend to be more sharply confined. Extending margins of excision for the purpose of removing inapparent metastases is fallacious because the latter are rare, their localization cannot be foretold, and satellite metastases are usually associated with distant metastases, so that patients do not profit from early removal of cutaneous lesions. The only meaningful objective of excision is complete removal of the primary melanoma. The success of excision must be controlled histopathologically. Because of limitations of the method, a histopathologic safety margin should be observed that must depend on the characteristics of the individual lesion. In sharply confined melanomas, a histopathologic margin of at least 1 mm is sufficient. In the case of poor demarcation, with solitary atypical melanocytes extending far beyond the bulk of the lesion, a broader histopathologic safety margin is advisable. Special caution should be exercised in the presence of regression and for desmoplastic melanomas, acral melanomas, and melanomas on the face and scalp. Instead of wide and deep excisions with standardized margins, "personalized excisions" are required for primary cutaneous melanoma. The concept of clinical safety margins is a relic of former times that has no place in modern medicine.
引用
收藏
页码:884 / 896
页数:13
相关论文
共 50 条
  • [1] Personalized medicine: paradigm shift or revolution
    Hays, Priya
    [J]. GENETICS IN MEDICINE, 2019, 21 (07) : 1662 - 1662
  • [2] Personalized medicine: A paradigm shift in healthcare
    Liao, Wen-Ling
    Tsai, Fuu-Jen
    [J]. BIOMEDICINE-TAIWAN, 2013, 3 (02): : 66 - 72
  • [3] Personalized medicine and allergen immunotherapy: the beginning of a new era?
    Cristoforo Incorvaia
    Erminia Ridolo
    Diego Bagnasco
    Silvia Scurati
    Giorgio Walter Canonica
    [J]. Clinical and Molecular Allergy, 19 (1)
  • [4] Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: A paradigm shift
    Gupta, Pooja D.
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 (02) : 135 - 141
  • [5] A New Paradigm for Biospecimen Banking in the Personalized Medicine Era
    McDonald, Sandra A.
    Watson, Mark A.
    Rossi, Joan
    Becker, Colleen M.
    Jaques, David P.
    Pfeifer, John D.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 136 (05) : 679 - 684
  • [6] Shift from protocol-based to personalized medicine in active surveillance: beginning of a new era
    Loeb, Stacy
    [J]. BJU INTERNATIONAL, 2017, 120 (01) : 3 - 4
  • [7] The Histogenetic Model of Melanoma in the Modern Era of Personalized Medicine
    Roncati, Luca
    Piscioli, Francesco
    [J]. ACTA DERMATOVENEROLOGICA CROATICA, 2020, 28 (04) : 236 - 237
  • [8] Predictive biomarkers: a paradigm shift towards personalized cancer medicine
    Nicholas B. La Thangue
    David J. Kerr
    [J]. Nature Reviews Clinical Oncology, 2011, 8 : 587 - 596
  • [9] Predictive biomarkers: a paradigm shift towards personalized cancer medicine
    La Thangue, Nicholas B.
    Kerr, David J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (10) : 587 - 596
  • [10] Personalized medicine: A paradigm shift towards promising health care
    Annadurai, Kalaivani
    Danasekaran, Raja
    Mani, Geetha
    [J]. JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2016, 8 (01): : 77 - U86